Medications

What Is Saxenda? Liraglutide for Weight Loss Guide

GLP-1 Companion · 8 min read

Saxenda was a landmark approval when the FDA cleared it for chronic weight management in December 2014. For the first time, a medication that worked through the GLP-1 pathway was available specifically for obesity rather than type 2 diabetes. Nearly a decade later, newer agents have produced larger weight-loss results, but Saxenda and its generic equivalents remain relevant options for certain patients.

What Is Saxenda?

Saxenda is the brand name for liraglutide 3.0 mg, a GLP-1 receptor agonist manufactured by Novo Nordisk. It is administered as a once-daily subcutaneous injection using a pre-filled pen. Liraglutide was originally developed at a lower dose (up to 1.8 mg) for type 2 diabetes under the brand name Victoza, which the FDA approved in 2010. At the higher 3.0 mg dose, liraglutide produces stronger appetite suppression and greater weight loss, leading to its approval for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, or type 2 diabetes.

The SCALE Clinical Trial Program

The evidence base for Saxenda rests primarily on the SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence) trial program, a series of large randomized controlled trials conducted between 2011 and 2016.

• SCALE Obesity and Prediabetes (n=3,731): After 56 weeks, patients on liraglutide 3.0 mg lost an average of 8.4% of body weight versus 2.8% on placebo. Approximately 63% of participants achieved at least 5% weight loss.
• SCALE Diabetes (n=846): In patients with type 2 diabetes, liraglutide produced 6.0% weight loss at 56 weeks versus 2.0% for placebo.
• SCALE Maintenance (n=422): Patients who had already lost weight with a low-calorie diet and then received liraglutide maintained greater weight loss compared to those who switched to placebo.
• SCALE Sleep Apnea (n=359): Liraglutide significantly reduced the severity of obstructive sleep apnea compared to placebo, independent of weight loss.

Across the SCALE program, the typical weight loss range for patients who tolerated the full 3.0 mg dose was 5 to 8 percent of body weight — meaningful, but substantially less than what is now achievable with semaglutide or tirzepatide.

How Saxenda Works

Liraglutide mimics the endogenous hormone GLP-1 (glucagon-like peptide-1), which is secreted from intestinal L-cells in response to food intake. At the 3.0 mg dose used in Saxenda, the primary mechanism driving weight loss is central appetite suppression: liraglutide activates GLP-1 receptors in the hypothalamus and brainstem, reducing hunger and increasing satiety. It also slows gastric emptying, meaning food remains in the stomach longer and the feeling of fullness is prolonged after meals.

Dosing Titration Schedule

Saxenda uses a five-week titration protocol designed to minimize gastrointestinal side effects. Injections are given once daily at any time of day, with or without food, into the abdomen, thigh, or upper arm.

1. Week 1: 0.6 mg once daily
2. Week 2: 1.2 mg once daily
3. Week 3: 1.8 mg once daily
4. Week 4: 2.4 mg once daily
5. Week 5 onward: 3.0 mg once daily (maintenance dose)

If a patient cannot tolerate a given dose increase, the escalation can be paused for an additional week before attempting to advance again. At 16 weeks, if the patient has not lost at least 4% of their baseline body weight, the prescriber should reassess whether continuing Saxenda is appropriate.

Common Side Effects

Gastrointestinal side effects are the most frequently reported adverse events with Saxenda and are most pronounced during dose escalation.

• Nausea: reported by approximately 39% of participants in SCALE trials (vs. 14% placebo)
• Diarrhea: approximately 21% (vs. 9% placebo)
• Constipation: approximately 19% (vs. 9% placebo)
• Vomiting: approximately 15% (vs. 4% placebo)
• Injection site reactions: redness, bruising, or mild pain
• Decreased appetite and early satiety
• Headache and fatigue, especially early in treatment

Serious but Rare Risks

• Pancreatitis: Discontinue immediately if severe abdominal pain develops.
• Gallbladder disease: Cholelithiasis risk is elevated with rapid weight loss.
• Increased heart rate: Liraglutide raises resting heart rate by approximately 2-3 beats per minute on average.
• Thyroid C-cell tumors: Observed in rodent studies; Saxenda carries a black-box warning and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
• Suicidal ideation: FDA required a warning in 2023 for all weight-loss medications, including liraglutide.

Generic Liraglutide: A Major 2025 Development

In August 2025, Teva Pharmaceuticals received FDA approval for the first generic version of liraglutide 3.0 mg for weight management — a significant milestone that substantially reduced the cost of this treatment. Brand-name Saxenda had a list price of approximately $1,400 per month, which was a major barrier for many patients. Generic liraglutide became available at roughly 20 to 40 percent of that cost, improving access for patients whose insurance plans now cover generic alternatives. As of early 2026, several other manufacturers are also expected to receive approvals, which should further reduce pricing.

Who Is Saxenda Still Appropriate For?

With the availability of semaglutide (Wegovy) and tirzepatide (Zepbound), which produce substantially greater weight loss, Saxenda is no longer a first-line choice for most patients starting GLP-1 therapy. However, there are specific circumstances where liraglutide 3.0 mg remains a reasonable option:

• Medicaid and state insurance coverage: Some Medicaid programs and state-level insurance formularies cover liraglutide but not semaglutide or tirzepatide for obesity.
• Cost sensitivity: Generic liraglutide is now substantially cheaper than brand Wegovy or Zepbound.
• Tolerability preference: A small subset of patients tolerates daily liraglutide better than weekly semaglutide.
• Prior authorization pathways: Certain employer health plans specifically include liraglutide on their obesity drug formulary.
• Pediatric use: Saxenda was approved in 2020 for adolescents aged 12 and older with a BMI at or above the 95th percentile — an indication not yet held by Wegovy-equivalent tirzepatide for the same age group.

How Saxenda Compares to Newer GLP-1 Options

The landscape of GLP-1 weight-loss medications has changed dramatically since Saxenda was approved. The STEP 1 trial demonstrated that semaglutide 2.4 mg (Wegovy) produces approximately 15 to 17 percent body weight loss — roughly double the results seen in SCALE. Tirzepatide 15 mg (Zepbound), a dual GIP/GLP-1 agonist, has shown even greater results of up to 20 to 22 percent in the SURMOUNT trials. For patients without access issues, these newer agents are clinically preferred. Saxenda occupies a niche role for cost-sensitive patients, those with specific formulary constraints, and adolescents.

The arrival of generic liraglutide is a genuine access improvement, but it does not change the clinical hierarchy: semaglutide and tirzepatide produce substantially more weight loss. The best choice for a given patient depends on efficacy goals, insurance coverage, and cost.

The Bottom Line

Saxenda (liraglutide 3.0 mg) was the first GLP-1 medication approved for weight management and has a strong, well-characterized evidence base from the SCALE trials. While newer GLP-1 agents now outperform it on efficacy, the 2025 approval of generic liraglutide has renewed Saxenda's relevance for cost-sensitive patients and those with specific insurance constraints. If you are considering liraglutide for weight management, consult your healthcare provider about whether the generic option fits your treatment goals and coverage situation.

Sources

• Saxenda (liraglutide 3.0 mg) Prescribing Information. Novo Nordisk.
• Pi-Sunyer et al. (2015). Liraglutide 3.0 mg in Weight Management. NEJM.